A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: Protocol and statistical considerations
Version 2 2024-06-06, 06:35
Version 1 2020-03-01, 00:00
journal contribution
posted on 2024-06-06, 06:35 authored by AT Reutens, K Jandeleit-Dahm, M Thomas, A Salim, AM De Livera, LA Bach, PG Colman, TME Davis, EI Ekinci, G Fulcher, PS Hamblin, MA Kotowicz, RJ MacIsaac, C Morbey, D Simmons, G Soldatos, G Wittert, T Wu, ME Cooper, JE ShawA physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: Protocol and statistical considerations
History
Related Materials
- 1.
Location
United StatesLanguage
EnglishPublication classification
C1 Refereed article in a scholarly journalJournal
Contemporary Clinical TrialsVolume
90Article number
ARTN 105892Pagination
1 - 8ISSN
1551-7144eISSN
1559-2030Publisher
ELSEVIER SCIENCE INCUsage metrics
Categories
No categories selectedKeywords
Science & TechnologyLife Sciences & BiomedicineMedicine, Research & ExperimentalPharmacology & PharmacyResearch & Experimental MedicineDiabetic nephropathyNADPH oxidaseType 1 diabetesAlbuminuriaCKD111502 Clinical Pharmacology and Therapeutics3214 Pharmacology and pharmaceutical sciences3202 Clinical sciences3205 Medical biochemistry and metabolomics
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC